U. Bruntsch

1.1k citations

55 papers · 834 indexed · h-index 16

Impact in

Otorhinolaryngology top 5%
- Head and Neck Cancer Studies
Oncology top 10%
- Cancer Treatment and Pharmacology

Papers in ⓘ

Oncology 21
- Cancer Treatment and Pharmacology 7
- Neutropenia and Cancer Infections 4
Surgery 15
- Nausea and vomiting management 6

Co-authors: W. M. Gallmeier (21 shared papers)M. Clavel (5 shared papers)Joseph Boni (1 shared paper)Cornelis J.A. Punt (1 shared paper)Marlies Peters (1 shared paper)J. Renard (7 shared papers)J. Wanders (8 shared papers)Jaap Verweij (6 shared papers)
Journals: European Journal of Cancer (5 papers)Annals of Oncology (4 papers)Cancer Chemotherapy and Pharmacology (3 papers)Investigational New Drugs (2 papers)Journal of Cancer Research and Clinical Oncology (2 papers)
Partner nations: Germany Netherlands Switzerland

In The Last Decade

U. Bruntsch

51 papers receiving 786 citations

Peers

Countries citing papers authored by U. Bruntsch

Since Specialization

Citations

This map shows the geographic impact of U. Bruntsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by U. Bruntsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites U. Bruntsch more than expected).

Fields of papers citing papers by U. Bruntsch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by U. Bruntsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by U. Bruntsch. The network helps show where U. Bruntsch may publish in the future.

Co-authors

The 25 scholars most cited alongside U. Bruntsch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with U. Bruntsch Line = papers co-authored together U. Bruntsch links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Annals of Oncology ·G. Catimel, Jan B. Vermorken, M. Clavel, PHM de Mulder, Ian Judson, C. Sessa, Martine Piccart, U. Bruntsch, Jaap Verweij, J. Wanders, (unknown), (unknown), (unknown), (unknown), (unknown)	1994	108
2	Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors Annals of Oncology ·Cornelis J.A. Punt, Joseph Boni, U. Bruntsch, Marlies Peters, C. Thielert	2003	95
3	The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas European Journal of Cancer and Clinical Oncology ·R Abele, M. Clavel, P. Dodion, U. Bruntsch, S. Gundersen, John Smyth, J. Renard, M. van Glabbeke, Herbert M. Pinedo	1987	92
4	Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BMJ ·John F. Smyth, Robert E. Coleman, Malcolm Nicolson, W. M. Gallmeier, Robert Leonard, M A Cornbleet, Simon Allan, B.K. Upadhyaya, U. Bruntsch	1991	90
5	Moderate Dose Escalation for Advanced Stage Hodgkin’s Disease Using the Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Scheme and Adjuvant Radiotherapy: A Study of the German Hodgkin’s Lymphoma Study Group Blood ·Hans Tesch, Volker Diehl, B. Lathan, Dirk Hasenclever, M. Sieber, U. Rüffer, Andreas Engert, Jeremy Franklin, Michael Pfreundschuh, K.P. Schalk, G Schwieder, Gerburg M. Wulf, Gottfried Dölken, P. Worst, P. Koch, N. Schmitz, U. Bruntsch, C. Tirier, Ulrich Müller, Markus Loeffler	1998	48
6	Use of and attitudes held towards unconventional medicine by patients in a department of internal medicine / oncology and haematology Supportive Care in Cancer ·Herbert Kappauf, D Leykauf‐Ammon, U. Bruntsch, Markus Horneber, G. Kaiser, G. Büschel, W. M. Gallmeier	2000	43
7	Epirubicin in colorectal cancer Investigational New Drugs ·Eduard E. Holdener, Heine H. Hansen, H. F. HÖST, U. Bruntsch, Franco Cavalli, J. Renard, Herbert M. Pinedo, Marcel Rozencweig	1985	24
8	Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer. Journal of Clinical Oncology ·Marcel Rozencweig, W ten Bokkel Huinink, F. Cavalli, U. Bruntsch, P Dombernowsky, H. F. HÖST, V H Bramwell, G Renard, M. van Glabbeke, Genevieve Decoster	1984	23
9	Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group. PubMed ·Ferry A.L.M. Eskens, G. Greim, C. van Zuylen, Ingmar Wolff, Denis Lj, André Planting, F.A.J. Muskiet, J Wanders, Nicholas Barbet, Leslie Choi, R Capdeville, Jaap Verweij, A.-R. Hanauske, U. Bruntsch	2000	22
10	Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC early clinical trials group European Journal of Cancer ·U. Bruntsch, Bernhard Heinrich, S.B. Kaye, P.H.M. de Mulder, A. van Oosterom, Robert Paridaens, Jan B. Vermorken, J. Wanders, H. Franklin, M. Bayssas, Jaap Verweij	1994	21
11	Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group British Journal of Cancer ·Steven Kaplan, A.-R. Hanauske, N. Pavlidis, U. Bruntsch, A. te Velde, J. Wanders, Bernhard Heinrich, Jaap Verweij	1996	20
12	Combination chemotherapy with cisplatin, methotrexate, bleomycin, and vincristine (CABO) in advanced squamous cell carcinoma of the head and neck Cancer ·Marcel Rozencweig, P. Dodion, U. Bruntsch, W. M. Gallmeier, Michel Clavel, B Gignoux, H. Cortés Funes, Franc Cavalli, Anne Kirkpatrick, O. Dalesio, Marc van Rijmenant, (unknown)	1984	20
13	Microangiopathic hemolytic anemia, a frequent complication of mitomycin therapy in cancer patients European Journal of Cancer and Clinical Oncology ·U. Bruntsch, G. Groos, Franz-Jürgen Tigges, W. M. Gallmeier	1984	18
14	Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days. PubMed ·Ingmar Wolff, K Bench, Jos H. Beijnen, U. Bruntsch, Franco Cavalli, J. de Jong, Y. Groot, Olaf van Tellingen, J. Wanders, Cristiana Sessa	1996	16
15	Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study European Journal of Cancer ·Martin Schüler, U. Bruntsch, E. Späth‐Schwalbe, Hubert Schrezenmeier, Christian Peschel, L. Färber, Klaus J. Burger, J. Leißner, Christoph Huber, Walter E. Aulitzky	1998	15
16	Tropisetron in the prevention of chemotherapy-induced nausea and vomiting in patients responding poorly to previous conventional antiemetic therapy Annals of Oncology ·U. Bruntsch, E. Rüfenacht, Imelda Parker, S. Drechsler, K. de Bruijn	1993	15
17	Phase I Study of Weekly Oral Miltefosine (Hexadecyl-Phosphocholine) in Cancer Patients Oncology Research and Treatment ·S. Danhauser-Riedl, Anna Drozd, M. Zafferani, U. Bruntsch, M. Peukert, H. Sindermann, H Präuer, J. R. Siewert	1991	14
18	Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea Supportive Care in Cancer ·S. Drechsler, U. Bruntsch, Jochen Eggert, J. Grote-Kiehn, H. Gosse, Markus Bangerter, D. Ukena, C. Oehm, J. Mezger, L. Faerber, W. Imhoff, Michael Untch, W. M. Gallmeier	1997	13
19	Phase II study of 5?-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma Cancer Chemotherapy and Pharmacology ·P. Alberto, Marcel Rozencweig, M. Clavel, P Siegenthaler, Franco Cavalli, S. Gundersen, U. Bruntsch, J. Renard, Herbert M. Pinedo	1986	13
20	Prevention of Chemotherapy-Induced Nausea and Emesis in Patients Responding Poorly to Previous Antiemetic Therapy Drugs ·U. Bruntsch, S. Drechsler, E. Hiller, W. Eiermann, A. H. Tulusan, M. Bühner, R. Hartenstein, Hannah Koenig, W. M. Gallmeier	1992	12

About U. Bruntsch

U. Bruntsch is a scholar working on Oncology, Surgery, Molecular Biology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 55 papers that have together received 834 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (7 papers), Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (6 papers), Nausea and vomiting management (6 papers), Cancer therapeutics and mechanisms (6 papers), Lung Cancer Treatments and Mutations (6 papers), Neutropenia and Cancer Infections (4 papers) and Pharmacological Effects and Toxicity Studies (4 papers). The work is most often cited by research in Otorhinolaryngology (68 citations), Oncology (319 citations), Pathology and Forensic Medicine (107 citations), Hematology (66 citations) and Pulmonary and Respiratory Medicine (173 citations). U. Bruntsch has collaborated with scholars based in Germany, Netherlands and Switzerland. Frequent co-authors include W. M. Gallmeier, M. Clavel, Joseph Boni, Cornelis J.A. Punt, Marlies Peters, J. Renard, J. Wanders, Jaap Verweij, Herbert M. Pinedo and M. van Glabbeke. Their work appears in journals such as European Journal of Cancer, Annals of Oncology, Cancer Chemotherapy and Pharmacology, Investigational New Drugs and Journal of Cancer Research and Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact